KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Assets Average: 2019-2025

Historic Assets Average for Castle Biosciences (CSTL) over the last 6 years, with Sep 2025 value amounting to $553.8 million.

  • Castle Biosciences' Assets Average rose 10.54% to $553.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $553.8 million, marking a year-over-year increase of 10.54%. This contributed to the annual value of $492.3 million for FY2024, which is 9.32% up from last year.
  • As of Q3 2025, Castle Biosciences' Assets Average stood at $553.8 million, which was up 5.84% from $523.2 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Assets Average peaked at $553.8 million during Q3 2025, and registered a low of $426.1 million during Q2 2023.
  • Its 3-year average for Assets Average is $480.4 million, with a median of $472.9 million in 2024.
  • Its Assets Average has fluctuated over the past 5 years, first surged by 265.27% in 2021, then dropped by 5.98% in 2023.
  • Over the past 5 years, Castle Biosciences' Assets Average (Quarterly) stood at $448.1 million in 2021, then climbed by 0.99% to $452.6 million in 2022, then fell by 1.74% to $444.7 million in 2023, then grew by 17.59% to $522.9 million in 2024, then climbed by 10.54% to $553.8 million in 2025.
  • Its Assets Average stands at $553.8 million for Q3 2025, versus $523.2 million for Q2 2025 and $516.5 million for Q1 2025.